Table 3.
Treatment Outcomes of SNV
| Study | Number of Eyes | Baseline BCVA | Final BCVA | Mean CMT | F/u Duration (Months) | Mean No. of Injections (Intravitreal Bevacizumab) |
|---|---|---|---|---|---|---|
| Narayanan, 201248 | 16 | 20/120 | 20/70 | CMT decreased from 235.57±108.65 µm to 174.91± 56.97 µm | 12 | 1.9 |
| Abdelaziz, 201697 | 22 | 20/200 | 20/100 | – | 18 | 3 |
| Baz, 201798 | 10 | 0. 62 ± 0.35 logMAR | 0.54 ± 0.35 logMAR | CMT decreased from 251 ± 25 µm to 239 ± 39 µm | 54.7±16.0 | 1.7 |
| Ozkaya, 201399 | 26 | 20/100 | 20/40 | CMT decreased from 318 µm to 198 µm | 26 | 6 |
| Toygar, 2016100 | 25 | 20/91 | 20/62 | CMT decreased from 254 µ to 205 µm | 42± 34 | 8.4 |
| Roller, 2011101 | 9 | 0.48±0.29 (decimal) | 0.77± 0.35 (decimal) | CMT decreased from 328±139 µm to 265±142 µm | 26±11 | 2.3 |